Aldeyra Therapeutics, Inc. (ALDX)
Stock Price:
$7.64 USD
0.05 (0.66%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
295.16M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-49.26M |
| Shares Out |
38.63M |
| EPS (ttm) |
-1.73 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$7.64 |
| Previous Close |
$7.59 |
| Change ($) |
0.05 |
| Change (%) |
0.66% |
| Day's Open |
7.66 |
| Day's Range |
7.25 - 7.71 |
| Day's Volume |
266,831 |
| 52-Week Range |
1.48 - 8.70 |
More Stats
| Market Cap |
295.16M |
| Enterprise Value |
243.89M |
| Earnings Date (est) |
Apr 1, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
38.63M |
| Float |
35.30M |
| EPS (basic) |
-1.75 |
| EPS (diluted) |
-1.73 |
| FCF / Share |
-1.41 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.70M |
| Short Ratio |
2.50 |
| Short % of Float |
4.81% |
| Beta |
2.03 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.55 |
| Revenue |
n/a |
| Operating Income |
-48.66M |
| Net Income |
-49.26M |
| Free Cash Flow |
-42.48M |
| Net Cash |
51.26M |
| Net Cash / Share |
1.33 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-41.79% |
| ROE |
-82.02% |
| ROIC |
-163.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
6 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$26.83*
(251.18% upside)
Low
15.0
Current: $7.64
High
33.0
Target: 26.83
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | - | - | - | - | - | - |
| Operating Income | -63.07 | -39.70 | -22.49 | -18.70 | -11.99 | -7.27 | -3.68 |
| Net Income | -60.83 | -38.89 | -22.34 | -18.70 | -12.09 | -5.19 | 13.06 |
| Shares Outstanding | 27.11 | 21.69 | 15.92 | 11.35 | 8.63 | 3.82 | 0.32 |
| Earnings Per Share | -2.24 | -1.79 | -1.40 | -1.65 | -1.40 | -3.09 | -17.61 |
| Operating Cash Flow | -44.98 | -29.86 | -19.22 | -15.15 | -9.31 | -4.78 | -1.71 |
| Capital Expenditures | -0.01 | -0.26 | -0.02 | -0.01 | -0.09 | -0.01 | - |
| Free Cash Flow | -44.99 | -30.12 | -19.25 | -15.16 | -9.40 | -4.79 | -1.71 |
| Cash & Equivalents | 73.36 | 93.60 | 42.95 | 24.91 | 27.59 | 8.53 | 3.26 |
| Total Debt | 14.75 | - | 1.34 | 1.32 | 1.29 | 1.25 | 1.27 |
| Net Cash / Debt | 58.61 | 93.60 | 41.61 | 23.60 | 26.30 | 7.27 | 1.99 |
| Assets | 75.52 | 95.09 | 44.17 | 25.19 | 28.20 | 8.79 | 3.74 |
| Liabilities | 27.44 | 8.47 | 4.57 | 3.54 | 3.33 | 2.50 | 5.65 |
| Book Value | 48.08 | 86.62 | 39.60 | 21.65 | 24.88 | 6.28 | -40.22 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aldeyra Therapeutics, Inc. |
| Country |
United States |
| Employees |
10 |
| CEO |
Todd C. Brady |
Stock Information
| Ticker Symbol |
ALDX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ALDX |
| IPO Date |
May 2, 2014 |
Description
Aldeyra Therapeutics, a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.